Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial

• DOI: 10.1097/qad.0b013e32833ce566
• Publication Date: 2010-07-12T10:34:42Z
• Authors: Dominique Salmon-...; Christine Durier; Corinne Desaint; Lise Cuzin; Mathieu Surenaud; Nadine Ben Hamouda; Jean-Daniel Lelièvre; Bénédicte Bonnet; Gilles Pialoux; Isabelle Poizot-M...; Jean-Pierre Aboulker; Yves Lévy; Odile Launay
• Keywords: ELISPOT; Reactogenicity; Cellular immunity; Lipopeptide

French National Agency for Research on AIDS and Viral Hepatitis's HIV-LIPO-5 vaccine includes five HIV-1 peptides, containing multiple CD8 CD4 T-cell epitopes coupled to a palmitoyl tail. Whether immunogenicity varies with the dose is unknown.HIV-negative volunteers were randomized receive at 50 microg/lipopeptide (N = 32), 150 500 33) or placebo 34) weeks 0, 4, 12 24. HIV-1-specific (interferon-gamma ELISpot peripheral blood mononuclear cells cultured days) responses (peripheral cell lymphoproliferation) assessed baseline, after each injection week 48.Local reactions dose-dependent but no differences in systemic appeared between groups. Sustained (at least two separate occasions) response rates one given pool obtained 22 of 32 (69%), 21 33 (64%) 34 (62%) individuals LIPO-5 50, groups, respectively (P < 0.0001 all comparisons placebo). Cumulative 15 (47%), 18 (55%) (44%) At 48, persisted 47 91 (52%) recipients.Doses microg able elicit HIV-specific sustained healthy adults. Safety good doses appear appropriate further 'prime-boost' trials.